Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1998-12-8
|
pubmed:abstractText |
The aim of this study was to assess the natural history of patients after transfusion and the acceptability of a standardized biological follow-up. In 1995, during 1 month, in 13 French hospitals, a follow-up at 3 and 6 months after blood transfusion was proposed to all blood recipients who had not received any blood transfusion within the past 6 months (eligible patients): screening for red cell antibodies, alanine aminotransferase (ALT) activity and specific viral markers of hepatitis B (hepatitis B surface antigen and antibody to hepatitis virus core antigen), of hepatitis C (antibodies) and of Human Immunodeficiency Virus (antibodies). At the beginning of the study, 296 patients were followed for 6 months. A complete follow-up was available at 3 months for 183 patients (62%), at 6 months for 168 (57%) and after 6 months, 198 patients (67%) have been once followed. Of eligible patients, 76% were alive at six months. After transfusion, the incidence of red cell alloantibodies and elevated ALT concentration were respectively 4% and 17%. At 6 months, one patient had Hepatitis B surface antigen; the responsibility of blood transfusion was excluded. Within the first 24 hours, 68 patients (23%) required another blood transfusion and 42% of units were transfused to patients with malignant disease. Our study quantifies in real conditions the difficulty of a biological follow-up in a transfused population, mostly composed of patients that could not be followed in the hospital where they were transfused.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1246-7820
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
266-74
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9789966-Adult,
pubmed-meshheading:9789966-Aged,
pubmed-meshheading:9789966-Alanine Transaminase,
pubmed-meshheading:9789966-Blood Group Incompatibility,
pubmed-meshheading:9789966-Blood Transfusion,
pubmed-meshheading:9789966-Cohort Studies,
pubmed-meshheading:9789966-Feasibility Studies,
pubmed-meshheading:9789966-Female,
pubmed-meshheading:9789966-Follow-Up Studies,
pubmed-meshheading:9789966-France,
pubmed-meshheading:9789966-Hepatitis B,
pubmed-meshheading:9789966-Hepatitis B Antibodies,
pubmed-meshheading:9789966-Humans,
pubmed-meshheading:9789966-Incidence,
pubmed-meshheading:9789966-Male,
pubmed-meshheading:9789966-Middle Aged
|
pubmed:year |
1998
|
pubmed:articleTitle |
[Feasibility of following up transfused patients].
|
pubmed:affiliation |
Centre national d'hémovigilance, Institut de santé publique d'épidémiologie et de développement, Bordeaux, France.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Multicenter Study
|